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osting by EAbstract The gene expression proﬁle p16, c-erbB-3 and bcl2 in hepatocellular carcinoma (HCC)
patients with and without associated HCV infection, was assessed. Forty-eight subjects were
included in the study and divided equally into two groups: HCC with and without HCV associated
infection. Adjacent paracancerous tissues were assessed as control samples. Correlations with var-
ious clinico-pathological parameters of the tumour were assessed: stage, grade, and tumour size.
The c-erbB-3 oncogene was expressed in 83.33% (40/48) of the total HCC sample and in 31.25%
(15/48) of the noncancerous lesions. C-erbB-3 was expressed in 87.5% (21/24) of the HCC cases
with associated HCV infection and in 79.16% (19/24) of the HCC cases without associated HCV
infection. Gene expression of c-erbB-3 was signiﬁcantly correlated with the clinico-pathological
parameters of the tumour. P16 gene expression was found in 12.5% (6/48) of the total HCC sample
and in 25% (12/48) of the para-cancerous lesions. P16 was expressed in 12.5% (3/24) of HCC cases
with and without associated HCV infection. Gene expression of p16 exhibited signiﬁcant negative
correlation with clinico-pathological parameters of the tumour. Bcl2 gene expression was found in
20.8% (10/48) of the total HCC sample and in the para-cancerous lesions. Bcl2 was expressed in418750; fax: +20 2 5280534.
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334 H.H. Fouad et al.20.8% (5/24) of the HCC cases with and without HCV associated infection. Gene expression of bcl2
did not show signiﬁcant correlations with the clinico-pathological parameters of the tumour. In
conclusion, gene expression proﬁles of p16 and c-erbB-3 could be used as prognostic molecular
markers in HCC.
ª 2011 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Table 1 Clinico-pathological characteristics of the patients.
Age (years)
62.3 ± 7.5
Number of subjects
Gender
Male 38
Female 10
HCV
+ve by PCR 24
ve by PCR 24
Tumour stage
<III 30
PIII 18
Tumour size
P5 cm 20
<5 cm 28
Intrahepatic metastasis
With 17
Without 31
Carcinoma diﬀerentiation
Poor 16
Moderate or well 32Introduction
Hepatocellular carcinoma (HCC) is one of the most common
causes of death from cancer in several regions in the world
including Egypt. In spite of enormous efforts to improve clin-
ical treatment, HCC remains a major carcinoma with high
mortality. Poor differentiation, larger size, portal invasion
and intra-hepatic metastasis are known to shorten disease-free
survival with this carcinoma. One of the most prominent
parameters in the evaluation of the biological aggressiveness
of carcinoma is cell behavior. Growth factor receptors with
tyrosine kinase activity are known to contribute greatly to
the regulation of cell behavior such as cell growth, prolifera-
tion and mortality [1,2]. The type I family of growth factor
receptors is the most prominent and is recognized as a pro-
to-oncogene family. The family includes c-erbB-3 [3,4]. When
speciﬁc ligands bind to a receptor of the family, the receptor
is activated by phosphorylation of the tyrosine residue in the
molecule [1]. It then forms a dimer with another receptor of
this family, causing activation by transphosphorylation, which
contributes to a variety of growth signal transductions [5].
These receptors share high sequence identity with each other
and are co-expressed in various combinations in neoplasms.
Thus far, of the four receptors of the family, the expression
of c-erbB-3 has been investigated in various neoplasms, includ-
ing malignancies of the liver and the biliary tract [6–8].
Although the mechanisms of hepatocellular carcinogenesis
are not yet expounded, alterations of some oncogenes, tumour
suppressor genes and apoptosis/antiapoptosis signaling, have
been reported in hepato-carcinogenesis. Some cell cycle tu-
mour suppressor genes such as p16 have been proved to be in-
volved in hepatocellular carcinogenesis. P16INK4a is a cell
cycle tumour suppressor that acts as competitive inhibitor by
binding directly to CDK4 and CDK6 and preventing their
association with a cyclin, which in turn arrests the cells in late
G1 phase of the cycle with pRB in a hypophosphorylated state
[9]. On the other hand, hepatitis C virus (HCV) infection was
proved to be closely linked to the development of HCC and
HCV may be the second important factor in HCC etiology
[10–12]. The molecular mechanisms involved in hepato-carci-
nogenesis of HCV remain poorly understood. Up to now,
many authors have believed that HCV cannot directly change
the structure of host genes such as the hepatitis B virus by inte-
gration because HCV is a RNA virus. Therefore, the effect of
HCV on factors controlling the cell cycle, apoptosis and onco-
genes, is an important ﬁeld of study in hepatocarcinogenesis
research [13,14].
On the other hand, the bcl-2 gene family is a group of apop-
tosis-related genes that is studied extensively at present [15].
Accumulated reports show that there is a high-level expression
of bcl-2 in many tumour tissues [16]. Primary HCC is a very
common malignant tumour in Egypt. There are speciﬁccharacteristics in the expression of bcl-2 in HCC [17,18]. Yildiz
et al. [19] stated that bcl-2 is highly expressed in B and
C hepatitis and in hepatocellular carcinomas. The high inci-
dence of bcl-2 activity in the non-neoplastic liver parenchyma
of HCC cases suggest that bcl-2 activation may be involved in
the development of at least some cases of HCC.
The present study was conducted to evaluate the gene
expression proﬁle of p16, c-erbB-3 and bcl2 in HCC patients
with and without HCV associated infection. Correlations with
various clinic-pathological parameters of the tumour were
assessed to ﬁnd whether the expression proﬁle of the
studied genes could be used as prognostic markers in HCC
patients.Material and methods
Tissue specimens
Ten percentage buffered formalin-ﬁxed parafﬁn-embedded
blocks of HCC were prepared from 48 patients who had
undergone surgery for HCC during the period from January
2009 to February 2010. Informed consent was obtained
from each patient. The clinico-pathological characteristics of
the patients are shown in Table 1. HCC was ranked using
the CLIP staging system. The survival rate at 12 months follow
up was 70% for patients with a CLIP score of less than
three, and 38.8% for patients with a CLIP score of more than
three.
Table 2 The oligonucleotide primers sequence of the studied genes.
Primer sequence Annealing temperature (C) Product size (bp)
c-erbB-3
Forwardprimer: 50-GCCTGGACTTGGAAGGCACCTG -30 58.5 348
Reverseprimer: 30-GAGCCACAGAGACCGCGTGA-50
GenBank Accession Number: GenBank: Z23134.1
P16 (CDKN2A)
Forwardprimer: 50-TCTCCGTTGGCCGGAGGTCA-30 59.5 260
Reverseprimer: 3’-TGCGCAGGTACCCTGCAACG-5’
GenBank Accession Number: NM_078487.2
Bcl2
Forward primer: 50-CGTCAACCGGGAGATGTCGCC-30 59 220
Reverse primer: 30-TGATTTTATTTCGCCGGCTCCACAG-50
GenBank Accession Number: NM_000657.2
Beta actin
Forward primer: 50-CGCGGCGGCGCCCTATAAA-30 59.5 397
Reverse primer: 30-ACCGTGCGATCCCCATTGGC-50
GenBank Accession Number: M10277.1
Fig. 1 PCR product of c-erbB-3 gene (348 bp).
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samples
Total RNA was extracted using RNeasy Puriﬁcation Reagent
(Promega, Madison, WI, USA), and then a sample (1 lg)
was reverse-transcribed with M-MLV (Moloney–Murine
Leukemia virus) reverse transcriptase (RT) for 30 min at
42 C in the presence of oligo-dT primer. Polymerase chain
reaction (PCR) was performed using the primers speciﬁed in
Table 2. PCR was performed for 45 cycles, with each cycle
consisting of denaturation at 95 C for 30 s, annealing at
58.5–59.5 C as speciﬁed for each primer pair for 30 s and elon-
gation at 72 C for one min, with an additional 10 min incuba-
tion at 72 C after completion of the last cycle. To exclude the
possibility of contaminating genomic DNA, PCRs were also
run without RT. Beta actin gene expression was assessed as
a positive control housekeeping gene. The PCR product was
separated by electrophoresis through a 1% agarose gel,
stained, and photographed under ultraviolet light.Fig. 2 PCR product of p16 gene (260 bp).Semi quantiﬁcation of PCR products by gel documentation
RT-PCR of the gene products was semi-quantiﬁed using a den-
sitometry gel documentation system (BioDocAnalyze, Biome-
tra, Goettingen, Germany) according to the manufacturer’s
speciﬁcation of the software. The amounts of PCR products
were evaluated according to the relative intensity of the studied
genes and beta actin bands by using the computed densitome-
try assay of the Biometra BioDoc Analyze System.Fig. 3 PCR product of bcl2 gene (220 bp).Statistical analyses
Values were expressed as mean ± S.D. The chi-squared test
and the Kruskal–Wallis test, followed by Dunn’s test of multi-
ple comparisons, were employed for analyses of the relation-
ship between the expression of the genes and various
clinicopathological parameters. A p value less than 0.05 was
considered to be statistically signiﬁcant. All the statistical anal-
yses were performed using SPSS version 10 software (SPSS,
Chicago, IL, USA).Results
In the present study, the c-erbB-3 oncogene was highly ex-
pressed in all HCC samples as compared to adjacent paracan-
cerous lesions (Fig. 1); the p16 gene was under-expressed in all
Fig. 4 PCR product of beta actin gene (397 bp).
Fig. 5 c-erb-B3 gene gel documentation by semiquantitative RT-
PCR density ratios. The gene was calculated in relation to the
internal standard beta-actin and expressed as means +SEM.
(* Signiﬁcant difference with beta actin). *p value <0.001.
Fig. 6 p16 gene documentation by semiquantitative RT-PCR
density ratios. *p value < 0.01.
Fig. 7 bcl2 gene documentation by semiquantitative RT-PCR
density ratios. *p value < 0.05.
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(Fig. 2); whereas the bcl-2 gene showed equal expression in
HCC samples as compared to paracancerous tissues (Fig. 3).
Beta actin gene was expressed in all samples (Fig. 4).
Moreover, c-erbB3 was over-expressed in HCC samples
with HCV associated infection as compared to HCC without
HCV associated infection (Fig. 5); whereas p16 and bcl-2 genes
were equally expressed in HCC samples with or without HCV
associated infection (Figs. 6 and 7).Furthermore, gene expression of c-erbB-3 showed signiﬁ-
cant positive correlation with the clinic-pathological parame-
ters of the tumour; p16 gene expression exhibited signiﬁcant
negative correlation with clinico-pathological parameters of
the tumour; whereas gene expression of bcl2 did not show
any signiﬁcant correlation with the clinico-pathological
parameters of the tumour (Table 3).
Discussion
In the present study, the c-erbB-3 oncogene was highly ex-
pressed in all HCC cases as compared to adjacent para-cancer-
ous lesions. Moreover, c-erbB3 was over-expressed in HCC
samples with HCV associated infection as compared to HCC
cases without HCV associated infection. Gene expression of
c-erbB-3 was signiﬁcantly correlated with the clinic-pathologi-
cal parameters of the tumour. Similar studies have been per-
formed on a few other carcinomas. For example, Sanidas
et al. [20] demonstrated that the c-erbB-3 protein was always
expressed in both gastric carcinoma and the adjacent mucosa,
but the expression level was usually higher in the carcinoma.
Travis et al. [21] observed that breast carcinoma expressed c-
erbB-3 more intensely and diffusely than the adjacent normal
glands, which were usually weakly or moderately positive for
this protein. Haugen et al. [22] showed that normal follicles
of the thyroid were all negative for c-erbB-3, whereas all types
of thyroid carcinoma expressed this protein with very high
incidence. The results of these studies, including ours, are sim-
ilar in that they show c-erbB-3 expression to be more diffuse
and/or more intense in the carcinoma nest than in normal or
benign lesions [23,24]. Our study also showed that c-erbB-3
expression in HCC was signiﬁcantly related to some important
markers of carcinoma progression, which are also predictors of
recurrence, such as stage, tumour size, intrahepatic metastasis
and carcinoma differentiation. Furthermore, c-erbB-3 itself, to
some extent, affects disease-free survival, as reported in several
studies [25,26].
To our knowledge there is no previous study conducted to
evaluate the role of c-erb-B3 in liver tissue with hepatitis C
virus, nor in HCV-associated HCC. However, El Bassuoni
et al. [27] reported that the elevated expression of another
member of the c-erbB family of oncogenes (C-erbB-2) in
HCV-related chronic liver disease may reﬂect pre-neoplastic li-
Table 3 Correlations between the expression of erbB-3, p16, bcl2 genes and various clinic-pathological features of HCC subjects.
Number of subjects Correlations with c-erb-B3 Correlations with p16 Correlations with bcl2
Tumour stage
PIII
<III
18
30
p< 0.001 p 6 0.05 NS
Tumour size
P5 cm
<5 cm
20
28
N.S. p 6 0.01 NS
Intrahepatic metastasis
With
Without
17
31
p< 0.01 p 6 0.05 NS
Carcinoma diﬀerentiation
Poor
Moderate or well
16
32
p< 0.001 p 6 0.01 NS
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liver disease or HCV carcinogens that enhance malignant
transformation.
As regards p16, the gene exhibited under-expression in all
HCC cases as compared to adjacent para-cancerous lesions.
Gene expression of p16 was equally expressed in HCC cases
with and without associated HCV infection. Moreover, gene
expression of p16 exhibited signiﬁcant negative correlation
with clinico-pathological parameters of the tumour. Jain
et al. [24] stated that loss of p16 protein could result from inac-
tivation of p16 by promoter hypermethylation, homozygous
deletions, and point mutations, and was noted in both early
and late stages of HCC [28]. Moreover, Hayashi et al. [29] sta-
ted that hypermethylation of p16 was one of the most impor-
tant alterations in HCV-associated HCC and that HCV could
play a role in hepato-carcinogenesis. Furthermore, Vivekanan-
dan and Torbenson [30] stated that epigenetic instability, man-
ifesting as methylation of important tumour suppressor gene
promoters, are associated with hepatocellular carcinomas that
arise in the setting of viral induced cirrhosis.
The frequently deleted chromosome regions by loss of het-
erozygosity (LOH) in HCCs contain many tumour suppressor
genes and some oncogenes, (p53, Rb, p16, PTEN, DLC1, and
IGF2R) [14,31]. LOH at chromosome 1p is usually seen in
early, small or well-differentiated HCC [32], whereas LOH at
chromosomes16p and 17p is more frequently associated with
HCCs in advanced stages, aggressive tumours, and poor prog-
nosis [33]. By comparative genomic hybridization (CGH),
chromosome 8p, 17p and 19p are associated with HCC metas-
tases [32].
On the other hand, several studies proved that loss of p16
gene expression was correlated with the cellular differentiation
of malignant tumours and an advanced grade of malignancy
[34,35]. The highly signiﬁcant correlation between p16 and
an advanced pathological grade of HCC was also conﬁrmed
in our study. Interestingly, the correlation of loss of p16 pro-
tein expression with the cellular differentiation of gastric can-
cer has been also reported [36]. Park et al. [37] also noted that
inactivation of p16 exon 1 by DNA hypermethylation oc-
curred during the progression of tumour cells to poorly differ-
entiated HCC, which was induced by diethylnitrosamine plus
thioacetamide in Fischer 344 rats. These studies suggested that
the aberrant alteration of mRNA expression and methylation
of p16 gene might be not only involved in HCC carcinogenesis
but also associated with its progress.As regards bcl2 gene expression, the gene was expressed to
an equal extent in all HCC cases and in all para-cancerous le-
sions. Bcl2 was equally expressed in HCC cases with and with-
out associated HCV infection. Gene expression of bcl2 did not
show signiﬁcant positive correlation to the clinic-pathological
parameters of the tumour.
Yang et al. [38] stated that the expression of bcl-2 protein in
most tumour tissues is stronger than that in the tissues of
origin. Nevertheless, most studies have demonstrated that
HCC tissues do not express or have only a low positive rate
of bcl-2 protein. Moreover, sometimes the positive rate of
bcl-2 in HCC tissues was lower than that in the non-tumour
liver tissues immediately adjacent to HCC tissues [39]. The
mechanism of this phenomenon is still unclear. There may be
speciﬁc characteristics of the regulation of bcl-2 in HCC. As re-
gards HCC cases with hepatitis C virus, results of the present
study coincided with the study of Tsamandas et al. [39] who
found bcl2 expression in liver biopsies with hepatitis B or C
viruses. Moreover, Yildiz et al. [19] studied bcl-2 gene expres-
sion in B and C hepatitis and hepatocellular carcinomas. The
authors stated that no causative relation between bcl-2 positiv-
ity and HCC could be implied; however the high incidence of
bcl-2 activity in the non-neoplastic liver parenchyma of the
HCC cases suggests that bcl-2 activation may be involved in
the development of at least some cases of HCC. Case control
and/or prospective studies are needed to show whether bcl-2
positivity in a chronic hepatitis case has a predictive value
for the development of HCC.
In conclusion, the c-erbB-3 gene was over-expressed in
HCC cases; whereas the p16 gene was under-expressed in
HCC cases. C-erbB-3 and p16 genes showed signiﬁcant corre-
lations with the clinico-pathological parameters of the sub-
jects; whereas bcl2 did not show any correlation with the
clinico-pathological parameters. Gene expression proﬁle of
p16 and c-erb-B3 could be used as prognostic molecular mark-
ers in HCC.Acknowledgements
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